Development of a Novel Prognostic Signature for Colorectal Cancer Based on Angiogenesis-related Genes

Overview

Journal Heliyon

Specialty Social Sciences

Date 2024 Jul 23

PMID 39040272

Authors

Aiqin Chen

Kailai Wang

Lina Qi

Wangxiong Hu

Biting Zhou

Affiliations

Soon will be listed here.

Abstract

Background: Colorectal cancer (CRC) is the third most common malignant tumor worldwide. Angiogenesis is closely related to tumor metastasis, which is the main cause of cancer death. Although several angiogenesis signatures have been proposed in some cancer types, no angiogenic signature has been developed to predict the prognosis and efficacy of antiangiogenic bevacizumab in CRC patients.

Methods: We developed a novel CRC angiogenic signature by refining seven publicly available angiogenic gene sets using least absolute shrinkage and selection operator (LASSO). Immune and stromal cells within the tumor microenvironment were compared between the high- and low-risk groups in more than 1000 CRC samples classified by calculating the risk score based on the customized angiogenic signature. The correlation of this new gene set with the efficacy of bevacizumab was also compared.

Results: A new prognostic-associated angiogenesis signature gene set was constructed that can divide CRC patients into two high- and low-risk groups. The high-risk angiogenic group was significantly associated with extracellular matrix organization, epithelial-mesenchymal transition (EMT), and myogenesis. In addition, the high-risk group had higher infiltration of stromal and immune cells and was more resistant to bevacizumab than the low-risk group.

Conclusion: Briefly, we constructed a novel angiogenic signature that can predict the prognosis of CRC patients and the efficacy of bevacizumab in treating CRC. Our results provide new insights into the relationships among angiogenesis, metastasis, and medication for CRC.

References

Liu W, Yu C, Li J, Fang J . The Roles of EphB2 in Cancer. Front Cell Dev Biol. 2022; 10:788587. PMC: 8866850. DOI: 10.3389/fcell.2022.788587. View

Stefansson I, Raeder M, Wik E, Mannelqvist M, Kusonmano K, Knutsvik G . Increased angiogenesis is associated with a 32-gene expression signature and 6p21 amplification in aggressive endometrial cancer. Oncotarget. 2015; 6(12):10634-45. PMC: 4496381. DOI: 10.18632/oncotarget.3521. View

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23):2335-42. DOI: 10.1056/NEJMoa032691. View

Yu G, Wang L, Han Y, He Q . clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284-7. PMC: 3339379. DOI: 10.1089/omi.2011.0118. View

Khong T, Thairu N, Larsen H, Dawson P, Kiriakidis S, Paleolog E . Identification of the angiogenic gene signature induced by EGF and hypoxia in colorectal cancer. BMC Cancer. 2013; 13:518. PMC: 4228238. DOI: 10.1186/1471-2407-13-518. View

Bai L, Wang F, Zhang D, Li C, Jin Y, Wang D . A plasma cytokine and angiogenic factor (CAF) analysis for selection of bevacizumab therapy in patients with metastatic colorectal cancer. Sci Rep. 2015; 5:17717. PMC: 4664961. DOI: 10.1038/srep17717. View

Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov J, Tamayo P . The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2016; 1(6):417-425. PMC: 4707969. DOI: 10.1016/j.cels.2015.12.004. View

Qi L, Chen J, Zhou B, Xu K, Wang K, Fang Z . HomeoboxC6 promotes metastasis by orchestrating the DKK1/Wnt/β-catenin axis in right-sided colon cancer. Cell Death Dis. 2021; 12(4):337. PMC: 8016886. DOI: 10.1038/s41419-021-03630-x. View

Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W . Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013; 4:2612. PMC: 3826632. DOI: 10.1038/ncomms3612. View

10.

Underwood T, Hayden A, Derouet M, Garcia E, Noble F, White M . Cancer-associated fibroblasts predict poor outcome and promote periostin-dependent invasion in oesophageal adenocarcinoma. J Pathol. 2014; 235(3):466-77. PMC: 4312957. DOI: 10.1002/path.4467. View

11.

Marisi G, Scarpi E, Passardi A, Nanni O, Pagan F, Valgiusti M . IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab. Cancer Manag Res. 2018; 10:5659-5666. PMC: 6241685. DOI: 10.2147/CMAR.S181570. View

12.

Juang Y, Jeng Y, Chen C, Lien H . PRRX2 as a novel TGF-β-induced factor enhances invasion and migration in mammary epithelial cell and correlates with poor prognosis in breast cancer. Mol Carcinog. 2016; 55(12):2247-2259. DOI: 10.1002/mc.22465. View

13.

Friedman J, Hastie T, Tibshirani R . Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw. 2010; 33(1):1-22. PMC: 2929880. View

14.

Sbierski-Kind J, Mroz N, Molofsky A . Perivascular stromal cells: Directors of tissue immune niches. Immunol Rev. 2021; 302(1):10-31. DOI: 10.1111/imr.12984. View

15.

Guinney J, Dienstmann R, Wang X, De Reynies A, Schlicker A, Soneson C . The consensus molecular subtypes of colorectal cancer. Nat Med. 2015; 21(11):1350-6. PMC: 4636487. DOI: 10.1038/nm.3967. View

16.

Mayakonda A, Lin D, Assenov Y, Plass C, Koeffler H . Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018; 28(11):1747-1756. PMC: 6211645. DOI: 10.1101/gr.239244.118. View

17.

Furuya K, Nakajima M, Tsunedomi R, Nakagami Y, Xu M, Matsui H . High serum proteinase-3 levels predict poor progression-free survival and lower efficacy of bevacizumab in metastatic colorectal cancer. BMC Cancer. 2024; 24(1):165. PMC: 10835931. DOI: 10.1186/s12885-024-11924-4. View

18.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

19.

Suenaga M, Mashima T, Kawata N, Wakatsuki T, Dan S, Seimiya H . Serum IL-8 level as a candidate prognostic marker of response to anti-angiogenic therapy for metastatic colorectal cancer. Int J Colorectal Dis. 2020; 36(1):131-139. DOI: 10.1007/s00384-020-03748-y. View

20.

Carmeliet P, Jain R . Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011; 473(7347):298-307. PMC: 4049445. DOI: 10.1038/nature10144. View